Podcasts about Roche

This week on Skytalkers we are so thrilled to talk to the author and illustrator of the graphic novel, “Lucas Wars”, Laurent Hopman and Renaud Roche! In the interview we discuss:  The inspiration behind creating a graphic novel about George Lucas and the creation of Star Wars  The artistic decisions behind choosing which moments of George's life to highlight  How color plays a role in telling George's story throughout the graphic novel  The research and passion that Laurent and Renaud both brought to the project with their love of Star Wars  …and much, much more!  Click here to purchase “Lucas Wars”: https://amzn.to/4plEmX2 Join our Patreon community and unlock bonus episodes + more! Our website! Follow us on Twitter/X @skytalkerspod Follow us on TikTok @skytalkers Follow us on Facebook Follow us on Instagram @skytalkerspodcast Follow Charlotte on Twitter/X @crerrity Follow Caitlin on Twitter/X @caitlinplesher Email us! hello@skytalkers.com For ad inquiries please email: skytalkers@58ember.com Please note this Episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this Episode. Learn more about your ad choices. Visit megaphone.fm/adchoices

Ecoutez les infos de la Loire avec le flash info de 07h00 de ce mercredi 10 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de la Loire avec le flash info de 08h00 de ce mercredi 10 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de la Loire avec le flash info de 12h00 de ce mercredi 10 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de la Loire avec le flash info de 16h00 de ce mercredi 10 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

In this episode of Idea Collider, host Mike Rea interviews Dr. Christian Rommel from Bayer. Dr. Rommel discusses his journey in molecular oncology from the Max Planck Institute, through roles at Roche, to overseeing global R&D at Bayer. He shares insights on turning scientific discovery into novel medicines, collaboration between scientists and commercial teams, and the importance of maintaining scientific integrity. Dr. Rommel also delves into the impact of AI in drug development, the potential of genetic medicines, and the complexities of launching new medicines on a global scale. The conversation also touches on embracing failure, internal and external partnerships, and the evolving landscape of clinical translation. 00:00 Introduction and Guest Welcome00:25 Christian Rommel's Journey in Oncology03:02 The Importance of Collaboration in Innovation05:16 Balancing Risk and Reward in Drug Development18:07 The Role of AI and Data in Modern R&D22:33 Partnerships and External Learning26:16 Balancing Legacy and Innovation in Biotech27:18 Global Expansion and Leadership Diversity27:27 Courage in Biotech Management27:54 Inspiration from Roche Genentech30:26 Commitment to Product Supply and Market Readiness32:23 Challenges of Global Launches35:53 Emerging Trends in Pharma: AI and Genetic Medicines42:20 Decision-Making in Pharma47:30 Reflections on Academic and Professional Journey Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Christian Rommel;LinkedIn: https://www.linkedin.com/in/christian-rommel/Website: https://www.bayer.com/en/innovation/science-research-and-innovation Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Ecoutez les infos de la Loire avec le flash info de 16h00 de ce mardi 09 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de la Loire avec le flash info de 07h00 de ce mardi 09 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de la Loire avec le flash info de 12h00 de ce mardi 09 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de la Loire avec le flash info de 18h00 de ce mardi 09 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de la Loire avec le flash info de 19h00 de ce mardi 09 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de la Loire avec le flash info de 08h00 de ce mardi 09 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Recent pay offers to teachers are seen by the Public Service Commissioner as entirely reasonable. Primary teachers decided to reject its latest offer, while PPTA members are voting on the revised one. It includes increasing the number of days secondary teachers can be called back to work outside of term time. Commissioner Sir Brian Roche told Mike Hosking they have the ability to call them back for 10 more days a year, which is what's being asked. He says they're getting paid for this and just want teachers to be available for career development when students aren't at school. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Ecoutez les infos de la Loire avec le flash info de 08h00 de ce lundi 08 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de la Loire avec le flash info de 12h00 de ce lundi 08 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de la Loire avec le flash info de 07h00 de ce lundi 08 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de la Loire avec le flash info de 18h00 de ce lundi 08 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de la Loire avec le flash info de 19h00 de ce lundi 08 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de la Loire avec le flash info de 16h00 de ce lundi 08 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

durée : 00:03:35 - Le marché de François-Régis Gaudry - par : François-Régis Gaudry - Il arbore fièrement ses tentacules dans les taverna de Grèce, on le déguste a la gallega dans les bars à tapas espagnols, on le savoure en salade ou à la provençale dans le sud de la France, mais François-Régis Gaudry parle aujourd'hui du poulpe de roche ! Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Ecoutez les infos de la Loire avec le flash info de 17h00 de ce dimanche 07 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de la Loire avec le flash info de 09h00 de ce dimanche 07 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de la Loire avec le flash info de 16h00 de ce samedi 06 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de la Loire avec le flash info de 08h00 de ce samedi 06 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

bref, tout va mal. Et pourtant, la Bourse, elle, s'envole comme si de rien n'était. Dans ce Swiss Bliss du 6 septembre 2025, je décortique la schizophrénie totale des marchés : Pourquoi chaque chiffre économique pourri est accueilli avec des cotillons. Pourquoi Powell est attendu comme le Père Noël de Wall Street. Pourquoi la France pourrait rallumer la mèche d'une crise souveraine. Et pourquoi Trump transforme chaque amende européenne en menace commerciale.

Eyes by Hand: Prosthetics of Art and Healing (MIT Press, 2025) is a book about artificial eyes—about the artisans and artists who make them, and about the life-changing and sometimes life-saving experience of wearing them, as author Dan Roche has done for 15 years. Eye making is done by hand, for one person at a time, by a very small number of ocularists (fewer than 200 in the US); it is a slow, intricate, and unusually intimate process of molding, fitting, and painting that brings ocularist and patient together for many hours or even days.In Eyes by Hand, Dr. Roche describes the craft that goes into the making of an eye that looks uncannily real, as well as the psychological and emotional healing that such service brings to someone who has suffered the very visible trauma of eye loss—a loss that can go to the heart of self-identity.In an engaging, frankly fascinating fashion, Roche captures the intricacies of a profession whose techniques and culture have been remarkably consistent for 200 years. He explores, too, how that profession may now be facing a digital transformation in the form of scan-print-mail possibilities. Such a change might make prosthetic eyes more easily and cheaply available, though it may also risk the aesthetic qualities and intimate connection fundamental to the process of healing. This interview was conducted by Dr. Miranda Melcher whose book focuses on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. You can find Miranda's interviews on New Books with Miranda Melcher, wherever you get your podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Eyes by Hand: Prosthetics of Art and Healing (MIT Press, 2025) is a book about artificial eyes—about the artisans and artists who make them, and about the life-changing and sometimes life-saving experience of wearing them, as author Dan Roche has done for 15 years. Eye making is done by hand, for one person at a time, by a very small number of ocularists (fewer than 200 in the US); it is a slow, intricate, and unusually intimate process of molding, fitting, and painting that brings ocularist and patient together for many hours or even days.In Eyes by Hand, Dr. Roche describes the craft that goes into the making of an eye that looks uncannily real, as well as the psychological and emotional healing that such service brings to someone who has suffered the very visible trauma of eye loss—a loss that can go to the heart of self-identity.In an engaging, frankly fascinating fashion, Roche captures the intricacies of a profession whose techniques and culture have been remarkably consistent for 200 years. He explores, too, how that profession may now be facing a digital transformation in the form of scan-print-mail possibilities. Such a change might make prosthetic eyes more easily and cheaply available, though it may also risk the aesthetic qualities and intimate connection fundamental to the process of healing. This interview was conducted by Dr. Miranda Melcher whose book focuses on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. You can find Miranda's interviews on New Books with Miranda Melcher, wherever you get your podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/medicine

Eyes by Hand: Prosthetics of Art and Healing (MIT Press, 2025) is a book about artificial eyes—about the artisans and artists who make them, and about the life-changing and sometimes life-saving experience of wearing them, as author Dan Roche has done for 15 years. Eye making is done by hand, for one person at a time, by a very small number of ocularists (fewer than 200 in the US); it is a slow, intricate, and unusually intimate process of molding, fitting, and painting that brings ocularist and patient together for many hours or even days.In Eyes by Hand, Dr. Roche describes the craft that goes into the making of an eye that looks uncannily real, as well as the psychological and emotional healing that such service brings to someone who has suffered the very visible trauma of eye loss—a loss that can go to the heart of self-identity.In an engaging, frankly fascinating fashion, Roche captures the intricacies of a profession whose techniques and culture have been remarkably consistent for 200 years. He explores, too, how that profession may now be facing a digital transformation in the form of scan-print-mail possibilities. Such a change might make prosthetic eyes more easily and cheaply available, though it may also risk the aesthetic qualities and intimate connection fundamental to the process of healing. This interview was conducted by Dr. Miranda Melcher whose book focuses on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. You can find Miranda's interviews on New Books with Miranda Melcher, wherever you get your podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science

Eyes by Hand: Prosthetics of Art and Healing (MIT Press, 2025) is a book about artificial eyes—about the artisans and artists who make them, and about the life-changing and sometimes life-saving experience of wearing them, as author Dan Roche has done for 15 years. Eye making is done by hand, for one person at a time, by a very small number of ocularists (fewer than 200 in the US); it is a slow, intricate, and unusually intimate process of molding, fitting, and painting that brings ocularist and patient together for many hours or even days.In Eyes by Hand, Dr. Roche describes the craft that goes into the making of an eye that looks uncannily real, as well as the psychological and emotional healing that such service brings to someone who has suffered the very visible trauma of eye loss—a loss that can go to the heart of self-identity.In an engaging, frankly fascinating fashion, Roche captures the intricacies of a profession whose techniques and culture have been remarkably consistent for 200 years. He explores, too, how that profession may now be facing a digital transformation in the form of scan-print-mail possibilities. Such a change might make prosthetic eyes more easily and cheaply available, though it may also risk the aesthetic qualities and intimate connection fundamental to the process of healing. This interview was conducted by Dr. Miranda Melcher whose book focuses on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. You can find Miranda's interviews on New Books with Miranda Melcher, wherever you get your podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Eyes by Hand: Prosthetics of Art and Healing (MIT Press, 2025) is a book about artificial eyes—about the artisans and artists who make them, and about the life-changing and sometimes life-saving experience of wearing them, as author Dan Roche has done for 15 years. Eye making is done by hand, for one person at a time, by a very small number of ocularists (fewer than 200 in the US); it is a slow, intricate, and unusually intimate process of molding, fitting, and painting that brings ocularist and patient together for many hours or even days.In Eyes by Hand, Dr. Roche describes the craft that goes into the making of an eye that looks uncannily real, as well as the psychological and emotional healing that such service brings to someone who has suffered the very visible trauma of eye loss—a loss that can go to the heart of self-identity.In an engaging, frankly fascinating fashion, Roche captures the intricacies of a profession whose techniques and culture have been remarkably consistent for 200 years. He explores, too, how that profession may now be facing a digital transformation in the form of scan-print-mail possibilities. Such a change might make prosthetic eyes more easily and cheaply available, though it may also risk the aesthetic qualities and intimate connection fundamental to the process of healing. This interview was conducted by Dr. Miranda Melcher whose book focuses on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. You can find Miranda's interviews on New Books with Miranda Melcher, wherever you get your podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science-technology-and-society

Eyes by Hand: Prosthetics of Art and Healing (MIT Press, 2025) is a book about artificial eyes—about the artisans and artists who make them, and about the life-changing and sometimes life-saving experience of wearing them, as author Dan Roche has done for 15 years. Eye making is done by hand, for one person at a time, by a very small number of ocularists (fewer than 200 in the US); it is a slow, intricate, and unusually intimate process of molding, fitting, and painting that brings ocularist and patient together for many hours or even days.In Eyes by Hand, Dr. Roche describes the craft that goes into the making of an eye that looks uncannily real, as well as the psychological and emotional healing that such service brings to someone who has suffered the very visible trauma of eye loss—a loss that can go to the heart of self-identity.In an engaging, frankly fascinating fashion, Roche captures the intricacies of a profession whose techniques and culture have been remarkably consistent for 200 years. He explores, too, how that profession may now be facing a digital transformation in the form of scan-print-mail possibilities. Such a change might make prosthetic eyes more easily and cheaply available, though it may also risk the aesthetic qualities and intimate connection fundamental to the process of healing. This interview was conducted by Dr. Miranda Melcher whose book focuses on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. You can find Miranda's interviews on New Books with Miranda Melcher, wherever you get your podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Eyes by Hand: Prosthetics of Art and Healing (MIT Press, 2025) is a book about artificial eyes—about the artisans and artists who make them, and about the life-changing and sometimes life-saving experience of wearing them, as author Dan Roche has done for 15 years. Eye making is done by hand, for one person at a time, by a very small number of ocularists (fewer than 200 in the US); it is a slow, intricate, and unusually intimate process of molding, fitting, and painting that brings ocularist and patient together for many hours or even days.In Eyes by Hand, Dr. Roche describes the craft that goes into the making of an eye that looks uncannily real, as well as the psychological and emotional healing that such service brings to someone who has suffered the very visible trauma of eye loss—a loss that can go to the heart of self-identity.In an engaging, frankly fascinating fashion, Roche captures the intricacies of a profession whose techniques and culture have been remarkably consistent for 200 years. He explores, too, how that profession may now be facing a digital transformation in the form of scan-print-mail possibilities. Such a change might make prosthetic eyes more easily and cheaply available, though it may also risk the aesthetic qualities and intimate connection fundamental to the process of healing. This interview was conducted by Dr. Miranda Melcher whose book focuses on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. You can find Miranda's interviews on New Books with Miranda Melcher, wherever you get your podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/technology

Eyes by Hand: Prosthetics of Art and Healing (MIT Press, 2025) is a book about artificial eyes—about the artisans and artists who make them, and about the life-changing and sometimes life-saving experience of wearing them, as author Dan Roche has done for 15 years. Eye making is done by hand, for one person at a time, by a very small number of ocularists (fewer than 200 in the US); it is a slow, intricate, and unusually intimate process of molding, fitting, and painting that brings ocularist and patient together for many hours or even days.In Eyes by Hand, Dr. Roche describes the craft that goes into the making of an eye that looks uncannily real, as well as the psychological and emotional healing that such service brings to someone who has suffered the very visible trauma of eye loss—a loss that can go to the heart of self-identity.In an engaging, frankly fascinating fashion, Roche captures the intricacies of a profession whose techniques and culture have been remarkably consistent for 200 years. He explores, too, how that profession may now be facing a digital transformation in the form of scan-print-mail possibilities. Such a change might make prosthetic eyes more easily and cheaply available, though it may also risk the aesthetic qualities and intimate connection fundamental to the process of healing. This interview was conducted by Dr. Miranda Melcher whose book focuses on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. You can find Miranda's interviews on New Books with Miranda Melcher, wherever you get your podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/book-of-the-day

Ecoutez les infos de la Loire avec le flash info de 16h00 de ce vendredi 05 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de la Loire avec le flash info de 18h00 de ce vendredi 05 septembre 2025. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Dr. Sumanta (Monty) Pal and Dr. Petros Grivas discuss innovative new intravesical therapies and other recent advances in the treatment of non-muscle invasive bladder cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello and welcome. I'm Dr. Monty Pal here at the ASCO Daily News Podcast. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. And I'm really delighted to be your new host here. Today's episode is going to really sort of focus on an area near and dear to my heart, something I actually see in the clinics, and that's bladder cancer. We're specifically going to be discussing non-muscle invasive bladder cancer, which actually comprises about 75% of new cases. Now, in recent years, there's been a huge shift towards personalized bladder-preserving strategies, including innovative therapies and new agents that really are reducing reliance on more primitive techniques like radical cystectomy and radiation therapy. And I'm really excited about this new trend. And really at the forefront of this is one of my dear friends and colleagues, Dr. Petros Grivas. He's a professor in the Department of Medicine and Division of Hematology Oncology at the University of Washington. It's going to take a while to get through all these titles. He's taken on a bunch of new roles. He is medical director of the International Program, medical director of the Local and Regional Outreach Program, and also professor in the Clinical Research Division at the Fred Hutch Cancer Center. Petros, welcome to the program. Dr. Petros Grivas: Thank you so much, Monty. It's exciting for me to be here. Dr. Sumanta (Monty) Pal: Just FYI for our audience, our disclosures are available in the transcript of this episode.  We're going to get right into it, Petros. Non-muscle invasive bladder cancer, this is a really, really challenging space. We see a lot of recurrence and progression of the disease over time, about 50% to 70% of patients do have some recurrence after initial treatment, and about 30% are ultimately going to progress on to muscle-invasive or metastatic disease. Now, I will say that when you and I were in training, non-muscle invasive bladder cancer was something that was almost relegated to the domain of the urologist, right? They would use treatments such as BCG (Bacillus Calmette-Guérin) in a serial fashion. It was rare, I think, for you and I to really enter into this clinical space, but that's all changing, isn't it? I mean, can you maybe tell us about some of the new therapies, two or three that you're really excited about in this space? Dr. Petros Grivas: Monty, you're correct. Traditionally and conventionally, our dear friends and colleagues in urology have been managing patients with non-muscle invasive bladder cancer. The previous term was superficial bladder cancer. Now, it has changed, to your point, to non-muscle invasive bladder cancer. And this has to do with the staging of this entity. These tumors in superficial layers of bladder cancer, not invading the muscularis propria, the muscle layer, which makes the bladder contract for urine to be expelled. As you said, these patients have been treated traditionally with intravesical BCG, one of the oldest forms of immunotherapy that was developed back in the 1970s, and this is a big milestone of immunotherapy development. However, over the years, in the last 50 years, there were not many options for patients in whom the cancers had progression or recurrence, came back after this intravesical BCG. Many of those patients were undergoing, and many of them still may be undergoing, what we call radical cystectomy, meaning removal of the bladder and the lymph nodes around the bladder. The development of newer agents over the last several years has given the patients the option of having other intravesical therapies, intravesical meaning the delivery of drugs, medications inside the bladder, aiming to preserve the bladder, keep the bladder in place. And there are many examples of those agents. Just to give you some examples, intravesical chemotherapy, chemotherapy drugs that you and me may be giving intravenously, some of them can be given inside the bladder, intravesical installation. One example of that is a combination of gemcitabine and docetaxel. These drugs are given in sequence one after the other inside the bladder, and they have seen significant efficacy, good results, again, helping patients keeping the bladder when they can for patients with what we call BCG unresponsive non-muscle invasive bladder cancer. And again, there's criteria that the International Bladder Cancer Group and the FDA developed, how to define when BCG fails, when we have BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: And we're actually going to get into some of the FDA requirements and development pathways and so forth. What I'm really interested in hearing, and I'm sure our audience is too, are maybe some of the new intravesical treatments that are coming around. I do think it's exciting that the gemcitabine and docetaxel go into the bladder indeed, but what are some of the top new therapies? Pick two or three that you're excited about that people should be looking out for in this intravesical space. Dr. Petros Grivas: For sure, for sure. In terms of the new up-and-coming therapies, there are a couple that come to mind. One of them is called TAR-200, T-A-R 200. This agent is actually a very interesting system. It's an intravesical delivery of a chemotherapy called gemcitabine, the one that I just mentioned a few minutes ago, that is actually being delivered through what we call a pretzel, which is like a rounded [pretzel-shaped] structure working like an osmotic pump, and that is being delivered inside the bladder intravesically by urologists. And this drug is releasing, through the osmotic release mechanism, this chemotherapeutic drug, gemcitabine, inside the bladder. And this can be replaced once every 3 weeks in the beginning. And the data so far from early-phase trials are really, really promising, showing that this agent may be potentially regulatory approved down the road. So TAR-200 is something to keep in mind. And similarly, in the same context, there is a different drug that also uses the same mechanism, and this osmotic release, this pretzel, it's just encoded with a different agent. The different agent is an FGFR inhibitor, a target therapy called erdafitinib, a drug that you and me may give in patients with metastatic urothelial carcinoma if they have an FGFR3 mutation or fusion. And that drug is called TAR-210. Dr. Sumanta (Monty) Pal: And can I ask you, in that setting, do you have to have an FGFR3 mutation to receive it? Or what is the context there? Dr. Petros Grivas: So for TAR-210, TAR-2-1-0, usually there is a checking to see if there is an FGFR3 mutation or fusion. And the big question, Monty, is do we have adequate tissue, right? From a limited tissue on what we call the TURBT, right, that urologists do. And now there is a lot of development in technology, for example, urine circulating tumor DNA to try to detect these mutations in the urine to see whether the patient may be eligible for this TAR-210. Both of those agents are not FDA approved, but there are significant promising clinical trials. Dr. Sumanta (Monty) Pal: So now let's go to a rapid-fire round. Give us two more agents that you're excited about in this intravesical space. What do you think? Dr. Petros Grivas: There is another one called cretostimogene. It's a long name. Dr. Sumanta (Monty) Pal: They really make these names very easy for us, don't they? Dr. Petros Grivas: They are not Greek names, Monty, I can tell you, you know. Even my Greek language is having trouble pronouncing them. The cretostimogene, it's actually almost what we call a growth factor, a GM-CSF. The actual name of this agent is CG0070. This is a replicating mechanism where GM-CSF is replicating in cells. And this agent has shown significant results again, like the TAR-200, in BCG unresponsive non-muscle invasive bladder cancer. I would say very quickly, two agents that actually were recently approved and they're already available in clinical practice, is nadofaragene firadenovec, another long name. That's a non-replicating vector that has the gene of interferon alfa-2b that stimulates the immune system in the bladder. It's given once every 3 months. And the last one that was, as I mentioned, already FDA approved, it's an interleukin-15 superagonist. It's another long name, which is hard to pronounce, but I will give it a try. It's a drug that was recently actually approved also in the UK. The previous name was N-803. It's given together with BCG as a combination for BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: This is a huge dilemma, I think, right? Because if you're a practicing, I'm going to say urologist for the moment, I guess the challenge is how do you decide between an IL-15 superagonist? How do you decide between a pretzel-eluting agent? How do you decide between that and maybe something that's ostensibly, I'm going to guess, cheaper, like gemcitabine and docetaxel? What's sort of the current thinking amongst urologists? Dr. Petros Grivas: Multiple factors play into our account when the decision is being made. I discuss with urologists all the time. It's not an easy decision because we do not have head-to-head comparisons between those agents. As you mentioned, intravesical chemotherapy with gemcitabine and docetaxel has been used over the years and this is the lowest cost, I would say, the cheapest option with good efficacy results. Obviously, the nadofaragene firadenovec every 3 months and the interleukin-15 superagonist, N-803, plus BCG have also been approved. The question is availability of those agents, are they available? Are they reimbursed? Cost of those agents can come into play. Frequency of administration, you know, once every 3 months versus more frequent. And of course, the individual efficacy and toxicity data, preference of the patients; sometimes the provider, the urologist, may have something that they may be more familiar with. But we lack this head-to-head comparison. Of course, I want to make sure I mention that radical cystectomy may still be the option for appropriate patients. So that complicates also the decision making and has to be individualized, customized, and personalized, taking into account all those factors. And there is not one size fitting all. Dr. Sumanta (Monty) Pal: So I think we discussed five intravesical therapies. As you point out, and you know, I'm going to get some calls about this: I think I referred to radical cystectomy as being a more primitive procedure. Not true at all. I think it's something that still is, you know, a mainstay of management in this disease space. But I guess it gets even more complicated, am I right, Petros? Because now we have systemic therapies that we can actually apply in this non-muscle invasive setting for at this point, refractory disease. Can you maybe just give us a quick two-minute primer on that? Dr. Petros Grivas: Absolutely, and systemic therapies now come into play, as you said. And a classical example of that, Monty, came from the KEYNOTE-057 trial that we published about 6 years ago. This is intravenous pembrolizumab, given intravascularly, intravenously, as opposed to the previously discussed intravesical administration of agents. Pembrolizumab was tested in that KEYNOTE-057 trial and showed efficacy about, I would say, one out of five patients, about 20%, had a complete response of the tumor in the bladder in a year after starting the treatment. Again, it's hard to compare across different agents, but obviously when we give something intravenously, there is a risk of toxicity, side effects systemically, what we call immune-related adverse events. And this can also play in the decision making, right? When you have intravesical agents versus intravascular agents, there is different toxicity profiles in terms of systemic toxicity. But intravenous pembrolizumab has been an option, FDA approved, since, if I remember, it was early 2020 when this became FDA approved. There are other agents being tested in this disease, but like atezolizumab through the SWOG study that Dr. Black and Dr. Singh led, but atezolizumab is not FDA approved for this indication. Again, this is for BCG unresponsive, high-risk, non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: So maybe teach us how it works, for instance, at an expert center like the Fred Hutch. When you see a patient with non-muscle invasive bladder cancer, there's obviously the option of surgery, there's the intravesical therapies, which I imagine the urology team is still really at the helm of. But then, I guess there has to be consideration of all options. So you've got to bring up systemic therapy with agents like pembrolizumab. In that context, are you involved that early on in the conversation? Dr. Petros Grivas: That's a great discussion, Monty. Paradigm is shifting as we mentioned together. The urologists have been treating these patients and still they are the mainstay of the treaters, the managers in this disease. But medical oncologists come to play more and more, especially with the FDA approval of intravenous pembrolizumab about 5 years ago [GC1]  [KM2] . We have the concept of multidisciplinary bladder cancer clinic here at Fred Hutch and University of Washington. This happens every Tuesday morning, and we're very excited because it's a one-stop shop for the patients. We have the urologist, a medical oncologist, radiation oncologist, and experts from radiology and pathology, and we all review cases specifically with muscle-invasive bladder cancer. But every now and then, we see patients with BCG unresponsive non-muscle invasive bladder cancer. And this is where we discuss and we talk to the patient about pros and cons of all those options. And that's a classic example where medical oncologists may start to see those patients and offer their input and expertise. In addition to that, sometimes we have clinical trials, we may see these patients because there are systemic agents that may be administered in this setting. We have the SunRISe trial program that includes also a systemically administered checkpoint inhibitor. So that's another example where we see patients either in the context of multi-clinic or in individual solo clinics to counsel the patients about the pros and cons of the systemically administered agents in the context of clinical trials. Usually checkpoint inhibitors are the class of agents that are being tested in this particular scenario. Dr. Sumanta (Monty) Pal: I can see a scenario where it's really going to require this sort of deep dive, much in the way that we do for prostate cancer, for instance, where the medical oncologist is involved very early on and planning out any sort of systemic therapy component of treatment or at the very least, at least spelling out those options. I think it's going to be really interesting to see what this space looks like 5 or 10 years down the road. In closing, I wanted to go through something that I think is so different in this space, at least for the time being, and that is the paradigm for FDA approval. When you and I have our fellows in the clinics, we always say, “Look, you know, the paradigm in this disease and that disease and the other disease needs to be phase 3 randomized trials, right? Big thousand patient experiences where you're testing clinical endpoints.” That's tough in non-muscle invasive bladder cancer, right? Because thankfully, outcomes can actually be quite good, you know, in this setting, right? It's tough to actually estimate overall survival in some of these early-stage populations. Tell me what the current regulatory bar is, and this is a tough thing to do in 2 minutes or less but tell me where you see it headed. Dr. Petros Grivas: You alluded to that before, Monty, when I was giving the background and we talked about the regulatory approval. And I have to very quickly go back in time about 10 years ago because it's important for context that can help us in other disease types too. We had workshops with the FDA and the NCI with the help of the International Bladder Cancer Group and other colleagues. And we try to define a framework, what endpoints are meaningful for those patients in this disease. It was a multidisciplinary, multiple stakeholders meeting, where we tried to define what is important for patients. What are the available agents? What are the trial designs we can accept? And what are the meaningful endpoints that the regulatory agencies can accept for regulatory approval? And that was critical in that mission because it allowed us to design clinical trials, for example, single-arm trials in a disease where there was no standard of care. There was intravesical valrubicin and chemotherapy anthracycline that was approved for many years, but was not practically used in clinical practice, despite being approved, the valrubicin. And because of that, the FDA allowed these single-arm trials to happen. And obviously the endpoint was also discussed in that meeting. For example, for carcinoma in situ, complete response, clinical complete response, because the bladder remains intact in many patients, clinical complete response was a meaningful primary endpoint, also duration of response is also very important. So what is the durable clinical complete response in 1 year or 18 months is relevant. And when you have papillary tumors like Ta or T1 with CIS, for papillary tumors, event-free survival becomes one of the key endpoints and you look at it over time, for example, at 12 or 18 months, what is the event-free survival? So clinical complete response, duration of response, event-free survival, depending on the CIS presence or papillary tumors, I think these are endpoints that have allowed us to design those trials, get those agents approved.  Now, the question going forward, Monty, and we can close with that is, since now we have the embarrassment of riches, many more options available compared to where we were 6 and 7 years ago, is now the time to do randomized trials? And if we do randomized trials, which can be the control group? Which of those agents should be allowed to be part of the control group? These are ongoing discussions right now with the NCI, with other agencies, cooperative groups, trying to design those trials and move forward from here.[GC3]  Dr. Sumanta (Monty) Pal: Well, it's awesome to have you here on the program so we can get some early looks into some of these conversations. I mean, clearly, you're at the table at a lot of these discussions, Petros. So I want to thank you for sharing your insights with us today. This was just tremendous. Dr. Petros Grivas: Thank you, Monty. You know, patients in the center, I just came back from the Bladder Cancer Advocacy Network meeting in Washington, D.C., and we discussed all those questions, the topics you very eloquently mentioned and asked me today, and patients gave us great feedback and patients guide us in that effort. Thank you so, so much for having me and congratulations for the amazing podcast you're doing. Dr. Sumanta (Monty) Pal: Oh, cheers, Petros, thanks so much.  And thank you to the listeners who joined us today. If you really like the insights that you heard on this ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:      Dr. Sumanta (Monty) Pal  @montypal  Dr. Petros Grivas @PGrivasMDPhD   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Petros Grivas: Consulting or Advisory Role: Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology, Abbvie, Bicycle Therapeutics Replimune, Daiichi Sankyo, Foundation Medicine, Bicycle Therapeutics, Eli Lilly, Urogen Pharma, Tyra Biosciences Research Funding (Inst.): Bristol-Myers Squibb, Merck, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, ALX Oncology, Genentech Travel, Accommodations, Expenses: Gilead Sciences

The Public Service Commissioner says he doesn't want to see the public service slashed and burnt. Earlier this week, the New Zealand Initiative called for a culling of our 43 Government departments to just 20. Sir Brian Roche says everything's on the table - but the changes need to be measured. "The Initiative is one world view, I think these things have to evolve. I don't look at this being a big bang, we don't want to go through big slash/burn downsizings, those things are debilitating and I don't see those being required at this point." LISTEN ABOVESee omnystudio.com/listener for privacy information.

Healthcare systems continue to face intense workforce challenges, with nursing at the center of concern. According to the U.S. Bureau of Labor Statistics, employment of registered nurses is expected to grow 5% between 2024 and 2034—faster than the average growth across all jobs in the U.S. economy. While this growth reflects rising demand for healthcare services, especially among an aging population and patients managing chronic conditions, the greater challenge lies in workforce turnover. On average, more than 189,000 nursing positions will need to be filled each year to replace those leaving the profession due to retirements or career changes. Combined with post-pandemic burnout and competition from other sectors, these trends make workforce development, recruitment, and retention a critical priority for healthcare leaders across hospitals, outpatient centers, and home or residential care settings.How can healthcare leaders and academic partners work together to build a future-ready workforce that supports both patient care and long-term system stability?On this episode of I Don't Care by Dr. Kevin Stevenson, guest Geoffrey Roche, Senior Vice President for Healthcare Solutions at Risepoint, explores strategies for strengthening the pipeline of nurses, technologists, and other clinical roles. The conversation spans Roche's career in healthcare administration, academia, and EdTech, and highlights innovative models of workforce development from both the U.S. and abroad.Key Points from the Conversation…Early Engagement: Initiatives such as healthcare-focused high schools and apprenticeship programs can ignite interest before college and strengthen long-term retention.Breaking Barriers: Addressing waiting lists in clinical programs and offering paid roles for students creates a stronger path to licensure.Transformational Leadership: Healthcare systems need leaders invested in long-term workforce development, not transactional approaches focused only on immediate productivity.Geoffrey M. Roche is a national leader in healthcare workforce development, currently serving as Senior Vice President for Healthcare Solutions at Risepoint. He previously directed workforce strategy at Siemens Healthineers and held executive roles at Harrisburg University, Core Education, and Dignity Health Global Education, where he advanced health equity and built scalable education-to-workforce pipelines. Roche is also an adjunct professor and Forbes Business Council member, recognized for his expertise in leadership, healthcare innovation, and academic-industry collaboration.

Russ Branzell, President and CEO of CHIME, sits down with Dr. Okan Ekinci, CMIO & Global Head of Digital Technology at Roche Information Solutions, to explore the evolving roles of digital health in one of the world's largest biotech organizations. From aligning diagnostics and pharmaceutical innovation to enhancing cybersecurity and unlocking AI's clinical potential, Dr. Ekinci shares how Roche is navigating digital transformation in healthcare on a global scale. This insightful conversation also addresses the cultural and leadership shifts necessary to sustain innovation and ensure long-term impact in healthcare and life sciences.Key Takeaways:Key challenges and opportunities in integrating diagnostic data with treatment decisions.Emerging frameworks to overcome data silos and drive clinical interoperability.Biotech-specific cybersecurity threats and strategies for balancing protection with innovation.The top technologies transforming patient care and shaping the future of precision medicine.Leadership imperatives for building a culture of sustainable innovation in life sciences.

When Google reversed its decision to deprecate third-party cookies, the first word in ID5 CEO Mathieu Roche's mind was an expletive. But it doesn't really matter what happens with cookies on Chrome anymore. “Most of the industry has moved past the notion that cookies were good enough to target and measure advertising on the web,” Roche says.

Der Schweizer Pharmaindustrie wird der Handelsbilanzüberschuss mit den USA angelastet, der Zölle von 39% mit sich bringt. Roche-Konzernchef Thomas Schinecker betont jedoch den Beitrag der Branche zum Wohlstand der Schweiz sowie die grossen Investitionen seitens Roche in Forschung und Entwicklung. SMI -0.3%

An einer Veranstaltung des Arbeitgeberverbands Region Basel äusserte sich Roch-CEO Thomas Schinecker zu den US-Zöllen. Brisant waren seine Aussagen zur Beziehung Schweiz-EU.

This week we are so excited to bring you our conversation with Laurent Hopman and Renaud Roche, the creators of the upcoming incredible new graphic novel LUCAS WARS. If you don't know about it already, this book tells the epic story of the making of the original STAR WARS in a way never done before and we can't get enough of it. Hear all about how this book came to be, what's to come next and some big folks who've also loved the book. So get on your bike to pick up that TPM bootleg, listen today and celebrate the love! JOIN THE BLAST POINTS ARMY and SUPPORT BLAST POINTS ON PATREON! NEW ANDOR SEASON 2 EPISODE COMMENTARIES! COMMENTARIES FOR EVERY SKELETON CREW EPISODE! NEW EMPIRE STRIKES BACK COMMENTARY! Theme Music! downloadable tunes from episodes! Extra goodies! and so much MORE! www.patreon.com/blastpoints Blast Points T-SHIRTS are now available! Represent your favorite podcast everywhere you go! Get logo shirts while supplies last! Perfect for conventions, dates, formal events and more! Get them here: www.etsy.com/shop/Gibnerd?section_id=21195481 If you dug the show, please leave BLAST POINTS a review on iTunes, Spotify and share the show with friends! If you leave an iTunes review, we will read it on a future episode! Honestly! Talk to Blast Points on twitter at @blast_points "Like" Blast Points on Facebook Join the Blast Points Super Star Wars Chill Group here www.facebook.com/groups/ BlastPointsGroup/ we are also on Instagram! Wow! www.instagram.com/blastpoints Your hosts are Jason Gibner & Gabe Bott! contact BLAST POINTS at : contact@blastpointspodcast.com May the Force be with you, always! This podcast is not affiliated in any way with Lucasfilm Ltd. LLC, The Walt Disney Company, or any of their affiliates or subsidiaries.

(00:00) We start talking about Kowloon, but we quickly shift gears to Joe Murray’s knowledge of food! (18:54) Are the Boston Red legit or are they pretenders? Joe and Roche debate! (32:48) Looks like Bill Belichick is selling some of his real estate on Nantucket. (PLEASE be aware timecodes may shift up to a few minutes due to inserted ads) CONNECT WITH TOUCHER & HARDY: linktr.ee/ToucherandHardy For the latest updates, visit the show page on 985thesportshub.com. Follow 98.5 The Sports Hub on Twitter, Facebook and Instagram. Watch the show every morning on YouTube, and subscribe to stay up-to-date with all the best moments from Boston’s home for sports!

US-Präsident Trump will tiefere Medikamentenpreise und droht mit Zöllen. Nutzen Roche, Novartis und Co. den US-Markt aus? Und, warum fällt es der Branche so schwer Preise zu senken, angesichts der hohen Gewinne und Gehälter? Kritische Fragen an Interpharma-Geschäftsführer René Buholzer. Ergänzend zum Tagesgespräch finden Sie jeden Samstag in unserem Kanal die aktuelle Samstagsrundschau. Die Schweizer Pharma-Industrie steht gleich unter mehrfachem Druck aus den USA: einerseits soll sie die Preise senken für Medikamente in den USA und vermehrt im Land produzieren. Die Industrie hat Milliardeninvestitionen angekündigt, doch dem US-Präsidenten reicht das nicht. Bis Ende September soll die Industrie darlegen, wie sie die Medikamentenpreise, die teilweise ein Mehrfaches über denjenigen in Europa inklusive der Schweiz liegen, senken will. Gelingt das nicht drohen der Branche hohe Zölle. Die Hälfte aller Schweizer Pharma-Exporte gehen in die USA. Wie konnte die Branche so abhängig werden von einem Markt? Warum soll es trotz der hohen Margen im Geschäft nicht möglich sein, die Preise in den USA zu senken, ohne sie in Europa anzuheben? Was hat die Schweiz von Roche, Novartis und Co. tatsächlich? Und, nutzt die Branche die aktuelle Situation, um alte Forderungen nach weniger Regulierung durchzubringen? René Buholzer, der Chef von Interpharma, dem Verband der forschenden Pharmafirmen in der Schweiz, nimmt Stellung in der Samstagsrundschau bei Klaus Ammann.

BlackRock CEO Larry Fink has been appointed interim co-chair of the World Economic Forum, alongside Roche's André Hoffmann, as the organization recalibrates its governance model. It appears the old WEF needs a makeover, as many of the proposals they have been making are now facing defiance. State socialists and stockholder capitalists are now being undermined because of the bullishness from the Trump administration and others who are no longer convinced that their form of world government is key to sustainability models. The goal of the World Economic Forum is to weaponize the future and legitimize a New World Order. We are in a global ideological war between freedom and slavery. Listen to Ground Zero with Clyde Lewis M-F from 7-10 pm, pacific time on groundzeroplus.com. Call in to the LIVE show at 503-225-0860.

Networking for Introverts Who'd Rather Get a Root Canal I Greg Roche Networking advice was built for extroverts. Go to events. Make small talk. Collect business cards. For introverts, it feels like punishment. Exhausting. Fake. Pointless. Greg Roche—known as The Introverted Networker—disagrees. He's living proof you can grow a powerful network without awkward icebreakers, or pretending to be someone you're not. In this conversation, we expose the myths keeping executives stuck—and the truths that set introverts free: Why “I don't have time to network” is a myth How 15 minutes a day beats every networking event How to be “easy to help” so people actually follow through The mic drop: The more connected we get through technology, the less connected we are as humans—because we've outsourced our humanness to tech Plus, a simple, immediate action to restart your network today This isn't about becoming someone you're not. It's about using what makes you different to your advantage—and reclaiming the kind of human connection technology will never replace. Whether you're an introvert who dreads networking—or an extrovert who's been doing it wrong—you'll walk away with a playbook that actually works. Connect with Greg Roche: https://www.linkedin.com/in/gregsroche/ Get his book “The Fast and Easy Guide To Networking For Introverts” here If this episode hit home, do us a solid: leave a review on Apple Podcasts. It helps the show grow, and it helps more executives discover how to thrive in the hidden job market.

Billions are being poured into healthcare AI, yet most innovations never make it past pilot projects. Why? And more importantly—how do we fix it? In this episode of Med Tech Gurus, we sit down with Marco Smit, serial entrepreneur, life sciences executive, and AI commercialization expert. With leadership experience at Roche, Genentech, Gesund.ai, CareSyntax, and now Domelabs.ai, Marco has seen the full spectrum of healthcare AI—from hype to hard-earned success. He shares why so many organizations fall victim to “pilotitis”, the critical role of AI governance, and how startups and health systems can build scalable, evidence-driven solutions that actually deliver ROI. From navigating the complex regulatory landscape to choosing the right investors and partners, Marco offers a pragmatic playbook for moving AI from the lab to real clinical impact. Whether you're a startup founder, health system innovator, or medtech investor, this episode is packed with actionable insights on avoiding hype, accelerating adoption, and building AI solutions that last.

What happens when bureaucracy — the very operating system of most companies — becomes the biggest barrier to innovation, agility, and human potential?In this episode of The Conscious Capitalists' Summer Series, hosts Timothy Henry and Kate Adams speak with Michele Zanini, co-author of the Wall Street Journal bestseller Humanocracy and global expert on management innovation. Together, they explore how organizations can move beyond outdated, control-heavy structures to thrive in a future defined by radical uncertainty, technological disruption, and human ingenuity.Michele takes us inside bold organizational experiments — from Haier's micro-enterprise model in China to Buurtzorg's nurse-led healthcare revolution in the Netherlands — and explains how even giants like Roche are dismantling bureaucracy to become more agile and resilient. His message: organizations that unleash human creativity and distribute leadership will outpace those clinging to industrial-age hierarchy.This isn't just a conversation about management theory — it's a roadmap for building human-centered, future-ready companies that thrive in disruption and unlock the full potential of their people.Listeners will gain insights into:Why traditional bureaucratic models are collapsing — and what's replacing themHow Haier built an internal marketplace of micro-enterprises to fuel innovationBuurtzorg's “humanity over bureaucracy” approach to healthcare at scaleHow Roche transformed by shifting from command-and-control to empowermentThe principle of freedom within a framework — and how to apply itWhy unleashing human creativity is the ultimate competitive advantagePractical steps for leaders to future-proof their organizationsWhether you're a CEO fighting inertia, a startup founder designing for scale, or a leader ready to reimagine culture and structure, this episode offers powerful insights into how to build organizations that are truly capable of thriving into the future.**If you enjoy this podcast, would you consider leaving a review on Apple Podcasts/iTunes? It takes only a few seconds and greatly helps us get our podcast out to a wider audience.Please subscribe on Apple Podcasts / Spotify / Stitcher, or wherever you get your podcasts.For transcripts and show notes, please go to: https://www.theconsciouscapitalists.comThis show is presented by Conscious Capitalism, Inc. (https://www.consciouscapitalism.org/) and is produced by Rainbow Creative (https://www.rainbowcreative.co/) with Matthew Jones as Executive Producer, Rithu Jagannath as Lead Producer, and Nathan Wheatley as Editor.Thank you for your support!- Timothy & Kate

Join Bill Nowicki as he delves into the compelling life of Patrick Roche—a submariner shaped by family tradition, personal responsibility, and decades of experience beneath the waves. From growing up in a Navy family to serving on both diesel boats and missile submarines, Patrick shares intimate reflections on family, service, resilience, and camaraderie in the US Navy's Silent Service.   ### Highlights & Key Points **[00:00:00] - Beginnings in Groton & Naval Heritage** - Patrick grew up in Groton, Connecticut, with his father serving on submarines.   - Graduated high school in 1965; influenced by his father's Navy career.   - Joined the Navy after moving to San Diego (“I guess that's where I got the…”)   - Family tradition: Patrick and his father served together on the USS Ronquil (SS-396), completing three WestPac deployments to Japan and Vietnam.   **[00:03:00] - Life Aboard with Family** - Served with his father but led separate lives aboard; father was a chief quartermaster.   - Never faced negative bias due to his father's position.   Liberty meant different things for each—dad to the chief's club, Patrick and friends to the beach.   **[00:05:00] - Family Life & Responsibility** - Married at age 18, became a father early.   - Now the proud father of four daughters, eight grandchildren, and thirteen great-grandchildren.   - Emphasizes responsibility and “growing up quickly” as a driving force behind his life choices. **[00:09:00] - Naval Career & Historic Moments** - Started as a fireman apprentice with a guaranteed school for submariners.   - Went from diesel to nuclear ballistic missile submarines (SSBNs), including the USS Theodore Roosevelt (SSBN-600).   **[00:12:00] - Life and Duties on Submarines** - Served as an interior communications electrician (“IC man”), specializing as a gyro technician (explains the importance of gyros for navigation and missile launches).   - Patrolled with the George Bancroft (SSBN-643); recalls the predictability of SSBN rotations—three months on, three months off.   **[00:13:00] - Homecomings & Family Dynamics** - Kept family routines stable by letting his wife handle finances and household matters. - No issues adjusting to or from life at sea; credits strong partnership with his wife.   **[00:15:00] - Submarine Evolutions & Technological Changes** - Comments on advancements from older boats to modern fast attacks and Virginia-class submarines. - Describes watchstanding: battle helmsman responsibilities, auxiliary duties, and the unique experience of bunking arrangements.   **[00:19:00] - Challenges & Close Calls** - Survived a major flooding incident on the Roosevelt due to a head valve left open during snorkeling—highlights the ever-present dangers of submarine duty (“…we were down at 80-90 feet with the head valve open…”).   **[00:20:00] - Advancement, Brotherhood & Initiations** - Rose through the ranks to Chief in 12 years; shares stories of chief initiation rites. - Reminisces about camaraderie, qualification processes, and the support systems in place—especially as a “legacy” submariner.   **[00:24:00] - Civilian Career & Life After Service** - Transitioned to civilian roles with NAVSEA (Supervisor Shipbuilding), working in San Diego, New Orleans, and Bath, Maine. - Reflects on moving frequently for assignments, supervising ship construction.   **[00:25:00] - Retirement & Reflections** - Currently resides in Gales Ferry, Connecticut, after retiring 10 years ago. - Considers returning to Maine for its beauty and tranquility. - Stresses the importance of staying in touch with Navy friends and the legacy of the submarine community.   **[00:27:00] - The Holland Club & Submarine Brotherhood** - Member of the US Submarine Veterans' Holland Club—honoring 50+ years of qualification. - Describes the meaning of these traditions and the enduring bonds among submariners.   **[00:29:00] - Lasting Partnerships** - Acknowledges the unwavering support of his wife, Barbara, throughout their 60 years of marriage. - Offers closing reflections on the rewards of naval service and maintaining life-long friendships.   ---   ### Notable Quotes: - “I had a responsibility and had to do it.” - “People treated you a lot different, too, when you're not dink (delinquent in qualifications).” - “I just enjoyed being on the boats—wouldn't trade it for anything.” - “She [his wife] is a winner. Sixty years coming up in December.”   ---   ### Listen For: - Insights into multi-generational Navy life (00:00:00–00:04:00) - Early marriage and parenting in the military (00:05:00–00:07:00) - Historic submarine incidents (00:09:00–00:10:00) - Submarine technology and daily operations (00:12:00–00:16:00) - The legendary Holland Club tradition (00:27:00)   ---   ### Closing   **Want to hear more voices from beneath the waves? Subscribe and leave us a review!**   **Got a story to share, or questions for a guest? Email us or visit our site to connect.**   ---   **Contact & Resources:**   - Want to learn about the Holland Club? [USSVI Holland Club](https://www.ussvi.org/) - More about the Nautilus Memorial: [Submarine Force Museum](https://www.ussnautilus.org/)